XARELTO®: Dosing in the treatment and reduction in the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)

DOSING FOR DVT/PE TREATMENT AND RISK REDUCTION

15 mg

For the first 21 days, twice daily with food, at the same time each day in patients with a CrCl ≥30 mL/min

20 mg

Starting at day 22, once daily with food, at the same time each day for remaining treatment in patients with a CrCl ≥30 mL/min

Renal Dose Consideration
  • Avoid using XARELTO® in patients with CrCl <30 mL/min

A CONVENIENT 30-DAY STARTER PACK FOR PATIENTS WITH DVT/PE

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

*The decision regarding initiation setting should be based on the prescriber's clinical judgment.

CrCl = creatinine clearance.

General Tags: